Kura Oncology’s (KURA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock.

A number of other equities analysts have also recently issued reports on KURA. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a report on Monday. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Stock Performance

NASDAQ:KURA traded up $0.23 during trading hours on Wednesday, reaching $18.07. 70,185 shares of the stock were exchanged, compared to its average volume of 890,846. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The firm has a 50 day simple moving average of $18.90 and a 200-day simple moving average of $20.01. Kura Oncology has a 52 week low of $8.17 and a 52 week high of $24.17. The stock has a market capitalization of $1.38 billion, a P/E ratio of -8.00 and a beta of 0.86.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same period last year, the firm earned ($0.53) earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, sell-side analysts forecast that Kura Oncology will post -2.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KURA. Avoro Capital Advisors LLC boosted its stake in shares of Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after acquiring an additional 870,000 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Kura Oncology by 281.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after purchasing an additional 538,957 shares during the last quarter. Sofinnova Investments Inc. increased its stake in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares during the last quarter. Finally, Armistice Capital LLC grew its position in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.